^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia

Published date:
05/15/2020
Excerpt:
...entospletinib did not decrease leukemia burden in two KMT2A-AFF1 PDX models with NRAS/ or KRAS mutations, suggesting potential RAS-mediated resistance to SYK inhibition.
DOI:
10.3324/haematol.2019.241729